AHA News: Diabetes and Heart Failure Are Linked; Treatment Should Be Too

THURSDAY, June 6, 2019 (American Heart Association News) -- Having Type 2 diabetes or heart failure independently increases the risk for getting the other, and both often occur together, further worsening a patient's health, quality of life and care...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news

Related Links:

Conclusions: The models developed using insurance claims data could reliably predict the risk of MACRO in patients with T2DM and enabled patients at higher-risk of DKD to be identified in the absence of baseline diabetic nephropathy, CKD, or proteinuria. These models could help establish strategies to reduce the risk of MACRO in T2DM patients. PMID: 31625766 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
In this study, we aimed to evaluate the differential impact of DM2 on all-cause mortality in men vs women with HFpEF after admission for acute HF.MethodsWe prospectively included 1019 consecutive HFpEF patients discharged after admission for acute HF in a single tertiary referral hospital. Multivariate Cox regression analysis was used to evaluate the interaction between sex and DM2 regarding the risk of long-term all-cause mortality. Risk estimates were calculated as hazard ratios (HR).ResultsThe mean age of the cohort was 75.6 ± 9.5 years and 609 (59.8%) were women. The proportion of DM2 was similar betwe...
Source: Revista Espanola de Cardiologia - Category: Cardiology Source Type: research
AbstractAtrial fibrillation (AF) is common in patients with obesity and diabetes; the arrhythmia (if long ‐standing) is typically managed by rate‐control and anticoagulation. However, the coexistence of these two metabolic disorders complicates therapeutic options for rate‐control. The likely pathogenesis of AF in these patients is an expansion of epicardial adipose tissue, whose inflammation is t ransmitted to the left atrium causing electromechanical remodeling. However, this same process is also transmitted to the left ventricle, impairing its distensibility and its ability to tolerate volume, leading to heart fai...
Source: Journal of Cardiovascular Electrophysiology - Category: Cardiology Authors: Tags: COMPREHENSIVE REVIEWS Source Type: research
Evaluating stress levels over time and intervening when high perceived stress persists might reduce hypertension risk Related items fromOnMedica Should we recognise obesity as a disease? Type 2 diabetes in 10 times more young people than realised Pharmacists could offer high-dose statins direct to patients WHO dietary fat guidance fails to consider crucial evidence Plant-based diet linked to lower risk of heart failure
Source: OnMedica Latest News - Category: UK Health Source Type: news
AbstractHeart failure is one of the major cardiovascular complications in patients with type 2 diabetes mellitus (T2DM) and increases the risk of morbidity and mortality. Although active management for heart failure is needed in patients with T2DM, traditional treatment and some new class of antihyperglycemic drugs, such as glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-4 inhibitors, could not reduce the risk of heart failure. Recent major trials demonstrated sodium –glucose co-transporter-2 (SGLT2) inhibitors improve prognosis of T2DM patients through prevention of heart failure. Both heart failur...
Source: Journal of Echocardiography - Category: Cardiology Source Type: research
Metformin, the first choice drug for type 2 diabetes treatment in all stages of therapy, and one of the most widely prescribed anti-hyperglycemic agent worldwide, represents a rare example of an old drug which continues to display new beneficial effects in various fields. However, lactic acidosis (LA) persists as a serious adverse effect. LA incidence is low and is not necessarily determined by the administration of metformin. Unfortunately, the concern for this complication has negatively affected the drug use, particularly in chronic kidney disease, which may impair drug excretion, and in congestive heart failure and chr...
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research
Abstract OBJECTIVE: This umbrella review provides an overview of the consistency and gaps in the evidence base on eggs and cardiometabolic health. DESIGN: PubMed, Web of Science, Cochrane Library, the Nutrition Evidence Systematic Review and Agency for Healthcare Research and Quality databases were screened for evidence-based reviews in English that assessed human studies on egg consumption and cardiometabolic outcomes. RESULTS: Seven systematic reviews and fifteen meta-analyses were identified, with eighteen of these published since 2015. Overall, the systematic reviews were of low quality, while meta-a...
Source: Public Health Nutrition - Category: International Medicine & Public Health Authors: Tags: Public Health Nutr Source Type: research
Purpose of review In recent years, there have been several cardiovascular outcomes trials (CVOT) of two new classes of glucose-lowering medications: sodium–glucose cotransporter-2 inhibitors (SGLT2-i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA). It is important examine their potential for cardiovascular benefit and possible side effects among patients with type 2 diabetes (T2D) mellitus. Recent findings The current article reviews the findings of recent CVOT of SGLT2-i and GLP-1 RA, including their impact on cardiovascular events and relevant side effects. Summary For all T2D patients, with or wi...
Source: Current Opinion in Cardiology - Category: Cardiology Tags: ISCHEMIC HEART DISEASE: Edited by Peter H. Stone Source Type: research
Four large-scale trials in type 2 diabetes have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors prevent the occurrence of serious heart failure events. Additionally, the DAPA-HF trial demonstrated...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Commentary Source Type: research
AbstractIntroductionThe results of recently completed cardiovascular outcomes trials in patients with type 2 diabetes mellitus (T2DM) suggest that sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide (GLP) 1 receptor agonists have enhanced cardioprotective properties in patients with established cardiovascular disease (eCVD), but to a lesser degree in those without eCVD. SGLT2 inhibitors appear to be particularly beneficial in patients with heart failure. As recent data for the UK are lacking, we undertook to identify the percentage of T2DM patients with eCVD and heart failure in the UK.MethodsThis w...
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: Cardiology | Diabetes | Diabetes Type 2 | Endocrinology | General Medicine | Heart | Heart Failure